Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 315 articles:
HTML format



Single Articles


    November 2021
  1. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available


    September 2021
  2. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.
    PubMed    


  3. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    PubMed     Abstract available


    August 2021
  4. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available


  5. HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
    Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.
    PubMed    


  6. PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
    Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Br J Haematol. 2021;194:549-553.
    PubMed    


  7. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    PubMed    


    June 2021
  8. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.
    PubMed    


  9. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    PubMed     Abstract available


  10. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    PubMed     Abstract available


  11. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    PubMed     Abstract available


  12. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    PubMed     Abstract available


  13. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available


  14. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.
    PubMed    


  15. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.
    PubMed    


  16. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.
    PubMed    


  17. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    PubMed     Abstract available


  18. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    PubMed     Abstract available


  19. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.
    PubMed    


  20. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    PubMed     Abstract available


  21. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    PubMed     Abstract available


  22. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    PubMed     Abstract available


  23. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    PubMed     Abstract available


    May 2021
  24. ROSS DM
    How much imatinib is enough?
    Br J Haematol. 2021;193:699-700.
    PubMed    


  25. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    PubMed     Abstract available


  26. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    PubMed     Abstract available


  27. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    PubMed     Abstract available


  28. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    PubMed     Abstract available


  29. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    PubMed     Abstract available


  30. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.
    PubMed    


  31. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.
    PubMed    


  32. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    PubMed     Abstract available


  33. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    PubMed     Abstract available


  34. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    PubMed     Abstract available


    April 2021
  35. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available


  36. ZHENG J, Wu S, Hu Y, Gao L, et al
    Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
    Br J Haematol. 2021;193:197-200.
    PubMed    


  37. GANESAN P, Jain H, Bagal B, Subramanian PG, et al
    Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
    Br J Haematol. 2021;193:e1-e4.
    PubMed    


  38. FITTER S, Bradey AL, Kok CH, Noll JE, et al
    CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:171-175.
    PubMed     Abstract available


  39. TROUSSARD X, Grever MR
    The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
    Br J Haematol. 2021;193:11-14.
    PubMed    


  40. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available


  41. SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
    Br J Haematol. 2021;193:133-137.
    PubMed     Abstract available


  42. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available


  43. RASTOGI N, Baker S, Man S, Uger RA, et al
    Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
    Br J Haematol. 2021;193:155-159.
    PubMed     Abstract available


  44. GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
    Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
    Br J Haematol. 2021;193:129-132.
    PubMed     Abstract available


  45. STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
    Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Br J Haematol. 2021;193:325-338.
    PubMed     Abstract available


  46. DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
    Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    Br J Haematol. 2021;193:339-345.
    PubMed     Abstract available


  47. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:271-279.
    PubMed     Abstract available


  48. CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
    TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;193:346-355.
    PubMed     Abstract available


  49. DILLON R, Potter N, Freeman S, Russell N, et al
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
    Br J Haematol. 2021;193:231-244.
    PubMed     Abstract available


    March 2021
  50. HASSERJIAN RP
    Flow cytometry reveals the nuances of clonal haematopoiesis.
    Br J Haematol. 2021;192:949-950.
    PubMed    


  51. BECKER MW, Angelucci E
    A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
    Br J Haematol. 2021;192:800-802.
    PubMed    


  52. LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
    Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Br J Haematol. 2021;192:1054-1063.
    PubMed     Abstract available


  53. SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
    Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
    Br J Haematol. 2021;192:e148-e151.
    PubMed    


  54. FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
    Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Br J Haematol. 2021;192:e139-e144.
    PubMed    


  55. RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
    In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
    Br J Haematol. 2021;192:1068-1072.
    PubMed     Abstract available


  56. TIONG IS, Dillon R, Ivey A, Teh TC, et al
    Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Br J Haematol. 2021;192:1026-1030.
    PubMed     Abstract available


  57. QU S, Li B, Qin T, Xu Z, et al
    Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
    Br J Haematol. 2021;192:1006-1010.
    PubMed     Abstract available


  58. LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
    Parental origin of monosomy 7 in acute leukaemia.
    Br J Haematol. 2021;192:e132-e135.
    PubMed    


  59. KAYSER S, Hills RK, Langova R, Kramer M, et al
    Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Br J Haematol. 2021;192:832-842.
    PubMed     Abstract available


    February 2021
  60. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed     Abstract available


  61. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.
    PubMed    


  62. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.
    PubMed    


  63. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    PubMed     Abstract available


  64. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.
    PubMed    


  65. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.
    PubMed    


  66. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.
    PubMed    


  67. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed     Abstract available


  68. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed     Abstract available


  69. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed     Abstract available


  70. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed     Abstract available


    January 2021
  71. AKINOSOGLOU K, Paliogianni F, Spyridonidis A, Symeonidis A, et al
    SARS-CoV-2 persistence and non-protective immunity in infected haematological patients.
    Br J Haematol. 2021;192:e51-e54.
    PubMed    


  72. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.
    PubMed    


  73. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    PubMed     Abstract available


  74. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.
    PubMed    


  75. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    PubMed     Abstract available


  76. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.
    PubMed    


  77. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.
    PubMed    


  78. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    PubMed     Abstract available


  79. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.
    PubMed    


  80. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.
    PubMed    


  81. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    PubMed     Abstract available


  82. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    PubMed     Abstract available


  83. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    PubMed     Abstract available


  84. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    PubMed     Abstract available


  85. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    PubMed     Abstract available


    December 2020
  86. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
    PubMed    


  87. NELSON ND, McMahon CM, El-Sharkawy Navarro F, Freyer CW, et al
    Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia.
    Br J Haematol. 2020;191:935-938.
    PubMed    


  88. CHEN J, Wang F, Fang J, Nie D, et al
    Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.
    Br J Haematol. 2020;191:e113-e116.
    PubMed    


  89. PARRY-JONES N, Joshi A, Forconi F, Dearden C, et al
    Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).
    Br J Haematol. 2020;191:730-737.
    PubMed    


  90. GANGAT N, Morsia E, Foran JM, Palmer JM, et al
    Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
    Br J Haematol. 2020;191:e120-e124.
    PubMed    


  91. MOORMAN AV, Schwab C, Winterman E, Hancock J, et al
    Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
    Br J Haematol. 2020;191:844-851.
    PubMed     Abstract available


  92. MERYK A, Kropshofer G, Hutter J, Fritz J, et al
    Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
    Br J Haematol. 2020;191:816-824.
    PubMed     Abstract available


  93. SIBAI H, Chen R, Liu X, Falcone U, et al
    Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
    Br J Haematol. 2020;191:748-754.
    PubMed     Abstract available


  94. FRISCH A, Rowe JM, Ofran Y
    How we treat older patients with acute myeloid leukaemia.
    Br J Haematol. 2020;191:682-691.
    PubMed     Abstract available


    November 2020
  95. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
    PubMed    


  96. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available


  97. MONDELLO P, Zelenetz AD
    Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy.
    Br J Haematol. 2020;191:326-328.
    PubMed    


  98. CHAGALUKA G, Schwalbe EC, Chakumatha E, Carey P, et al
    Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting - the Blantyre experience.
    Br J Haematol. 2020;191:e87-e90.
    PubMed    


  99. CASSADAY RD, Marks DI, DeAngelo DJ, Jabbour EJ, et al
    Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
    Br J Haematol. 2020;191:e77-e81.
    PubMed    


  100. TUEUR G, Lazarian G, Eclache V, Fleury C, et al
    Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
    Br J Haematol. 2020;191:e90-e94.
    PubMed    


  101. MATTSSON A, Sylvan SE, Asklid A, Wiggh J, et al
    Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
    Br J Haematol. 2020;191:426-432.
    PubMed     Abstract available


  102. DERRIEUX C, Gish A, Caulier A, Grardel N, et al
    Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
    Br J Haematol. 2020;191:506-509.
    PubMed    


  103. IRANI YD, Hughes A, Clarson J, Kok CH, et al
    Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Br J Haematol. 2020;191:433-441.
    PubMed     Abstract available


    October 2020
  104. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
    PubMed    


  105. FOX TA, Troy-Barnes E, Kirkwood AA, Chan WY, et al
    Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
    Br J Haematol. 2020;191:194-206.
    PubMed     Abstract available


  106. CLARK RE
    Another set of guidelines for chronic myeloid leukaemia.
    Br J Haematol. 2020;191:147-149.
    PubMed    


  107. GILLEECE MH, Savani BN
    A stitch in time saves nine... MRD-based pre-emptive therapy.
    Br J Haematol. 2020;191:19-20.
    PubMed    


  108. BO A, Raiola AM, Gualandi F, Orengo G, et al
    Unintentional human leukocyte antigen-mismatched haematopoietic cell transplant: clinical course and root cause analysis.
    Br J Haematol. 2020;191:e35-e37.
    PubMed    


  109. MONTORO J, Chorao P, Quintero A, Roca J, et al
    Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation.
    Br J Haematol. 2020;191:12.
    PubMed    


  110. SMITH G, Apperley J, Milojkovic D, Cross NCP, et al
    A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
    Br J Haematol. 2020;191:171-193.
    PubMed    


  111. MCCLURE BJ, Heatley SL, Rehn J, Breen J, et al
    High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse.
    Br J Haematol. 2020;191:301-304.
    PubMed    


  112. RASHIDI A, Kaiser T, Ebadi M, Holtan SG, et al
    Circulating bacterial DNA and neutropenic fever during anti-leukaemia chemotherapy.
    Br J Haematol. 2020;191:e55-e58.
    PubMed    


  113. DONG S, Khedro T, Ward P, Dubeau L, et al
    First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2020;191:e52-e55.
    PubMed    


  114. KONG D, Qu C, Dai H, Li Z, et al
    CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph(+) mixed phenotype acute leukaemia with minimal residual disease.
    Br J Haematol. 2020;191:e47-e49.
    PubMed    


  115. KHALIFE R, Montroy J, Grigor EJM, Fergusson DA, et al
    Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.
    Br J Haematol. 2020;191:e14-e19.
    PubMed    


  116. PAUL S, Jammal N, Akhave N, Aung PP, et al
    Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia.
    Br J Haematol. 2020;191:e10-e13.
    PubMed    


  117. CERRANO M, Castella B, Lia G, Olivi M, et al
    Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:e28-e32.
    PubMed    


  118. RYLAND GL, Barraclough A, Fong CY, Fleming S, et al
    Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:123-126.
    PubMed    


  119. ZABKIEWICZ J, Lazenby M, Edwards G, Bygrave CA, et al
    Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
    Br J Haematol. 2020;191:231-242.
    PubMed     Abstract available


  120. WANG J, Mou N, Yang Z, Li Q, et al
    Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:212-222.
    PubMed     Abstract available


  121. GANZEL C, Wang XV, Rowe JM, Richards SM, et al
    At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
    Br J Haematol. 2020;191:37-43.
    PubMed     Abstract available


    September 2020
  122. ORF K, Rogosic S, Dexter D, Ancliff P, et al
    Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
    Br J Haematol. 2020;190:e274-e276.
    PubMed    


  123. SILLA L
    Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.
    Br J Haematol. 2020;190:e322-e323.
    PubMed    


  124. NESR G, Koshy R, Foldes D, Kagdi H, et al
    Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naive chronic lymphocytic leukaemia: a case report.
    Br J Haematol. 2020;190:e326-e328.
    PubMed    


  125. SMOLEJ L
    Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle.
    Br J Haematol. 2020;190:815-816.
    PubMed    


  126. EYRE TA
    Prognostication in Richter syndrome: context is everything.
    Br J Haematol. 2020;190:811-812.
    PubMed    


  127. CORBINGI A, Innocenti I, Tomasso A, Pasquale R, et al
    Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:901-908.
    PubMed     Abstract available


  128. SHOUMARIYEH K, Hussung S, Niemoller C, Bleul S, et al
    Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
    Br J Haematol. 2020;190:e339-e343.
    PubMed    


  129. DE PROPRIS MS, Intoppa S, Milani ML, Mariglia P, et al
    ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:e346-e349.
    PubMed    


  130. SAITO Y, Makita S, Chinen S, Kito M, et al
    Acute megakaryoblastic leukaemia with t(1;22)(p13.3;q13.1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour.
    Br J Haematol. 2020;190:e329-e332.
    PubMed    


  131. BRECCIA M, Vignetti M, Annibali O, Cottone F, et al
    Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
    Br J Haematol. 2020;190:e304-e307.
    PubMed    


  132. FOX LC, Tan M, Brown AL, Arts P, et al
    A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.
    Br J Haematol. 2020;190:e297-e301.
    PubMed    


  133. YAMANE T, Kawakami T, Sekiguchi N, Kobayashi J, et al
    High frequency of STAT3 gene mutations in T-cell receptor (TCR)gammadelta-type T-cell large granular lymphocytic leukaemia: implications for molecular diagnostics.
    Br J Haematol. 2020;190:e301-e304.
    PubMed    


  134. HANEKAMP D, Snel AN, Kelder A, Scholten WJ, et al
    Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
    Br J Haematol. 2020;190:891-900.
    PubMed     Abstract available


  135. OFFNER F, Robak T, Janssens A, Govind Babu K, et al
    A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
    Br J Haematol. 2020;190:736-740.
    PubMed     Abstract available


  136. TURKINA A, Wang J, Mathews V, Saydam G, et al
    TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
    Br J Haematol. 2020;190:869-876.
    PubMed     Abstract available


  137. VARGHESE AM, Sood N, Daniel SM
    Current pricing model for cancer drugs - is it 'Justum Pretium' for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration.
    Br J Haematol. 2020;190:e292-e294.
    PubMed    


  138. EL CHAER F, Ballen KK
    Treatment of acute leukaemia in adult Jehovah's Witnesses.
    Br J Haematol. 2020;190:696-707.
    PubMed     Abstract available


    August 2020
  139. RANGER A, Haji R, Kaczmarski R, Danga A, et al
    Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e128-e130.
    PubMed    


  140. PICIOCCHI A, Messina M, Soddu S, La Sala E, et al
    The COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.
    Br J Haematol. 2020;190:e211-e214.
    PubMed    


  141. FARAH N, Burt R, Ibrahim AR, Baker R, et al
    Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
    Br J Haematol. 2020;190:e208-e210.
    PubMed    


  142. CHOPRA J, Hiew HJ, Cumpstey A, Cagampang F, et al
    Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.
    Br J Haematol. 2020;190:e195-e198.
    PubMed    


  143. INNES AJ, Cook LB, Marks S, Bataillard E, et al
    Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
    Br J Haematol. 2020;190:e198-e200.
    PubMed    


  144. WILSON AJ, Troy-Barnes E, Subhan M, Clark F, et al
    Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
    Br J Haematol. 2020;190:e189-e191.
    PubMed    


  145. FARMER I, Okikiolu J, Steel M, Wanniarachchi C, et al
    Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.
    Br J Haematol. 2020;190:e248-e250.
    PubMed    


  146. LEISCH M, Greil R, Pleyer L
    IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
    Br J Haematol. 2020;190:314-317.
    PubMed    


  147. ANDREWS C, Maze D, Murphy T, Sibai H, et al
    Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
    Br J Haematol. 2020;190:467-470.
    PubMed    


  148. ZHU J, Raimbault A, Sourdeau E, Maillon A, et al
    Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry.
    Br J Haematol. 2020;190:e255-e258.
    PubMed    


  149. GLAVEY SV, Flanagan L, Bleach R, Kelly C, et al
    Secondary plasma cell leukaemia treated with single agent venetoclax.
    Br J Haematol. 2020;190:e242-e245.
    PubMed    


  150. CHOWDHURY A, Loaiza S, Yebra-Fernandez E, Nadal-Melsio E, et al
    An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets.
    Br J Haematol. 2020;190:e236-e239.
    PubMed    


  151. FIEDLER W, Chromik J, Amberg S, Kebenko M, et al
    A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
    Br J Haematol. 2020;190:e169-e173.
    PubMed    


  152. NIE D, Zhang J, Xiong M, Wang F, et al
    Complete remission of refractory juvenile acute myeloid leukaemia with RUNX1-PRDM16 in Bloom syndrome after haematopoietic stem cell transplantation.
    Br J Haematol. 2020;190:e166-e169.
    PubMed    


  153. PETERLIN P, Cluzeau T, Jullien M, Ngo Nloga AM, et al
    Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Br J Haematol. 2020;190:461-464.
    PubMed    


  154. LOKE J, Lowe DM, Miller LJ, Morton S, et al
    Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?
    Br J Haematol. 2020;190:311-313.
    PubMed    


  155. LEBLANC FR, Pearson JM, Tan SF, Cheon H, et al
    Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
    Br J Haematol. 2020;190:405-417.
    PubMed     Abstract available


  156. WANG J, Lu R, Wu Y, Jia J, et al
    Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2020;190:533-544.
    PubMed     Abstract available


  157. WILHELMSON AS, Porse BT
    CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
    Br J Haematol. 2020;190:495-507.
    PubMed     Abstract available


  158. SAGLIO G, Gale RP
    Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
    Br J Haematol. 2020;190:318-327.
    PubMed     Abstract available


  159. HERUDKOVA Z, Culen M, Folta A, Jeziskova I, et al
    Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
    Br J Haematol. 2020;190:562-572.
    PubMed     Abstract available


    July 2020
  160. GESTRICH CK, Sadri N, Sinno MG, Pateva I, et al
    Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Br J Haematol. 2020 Jul 29. doi: 10.1111/bjh.17000.
    PubMed    


  161. BLENNERHASSETT R, Kwan J, Coyle L, Wong K, et al
    Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes-a short report from two Sydney centres.
    Br J Haematol. 2020 Jul 28. doi: 10.1111/bjh.16998.
    PubMed    


  162. BARNEA SLONIM L, Ma S, Behdad A, Chen Q, et al
    Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Br J Haematol. 2020 Jul 17. doi: 10.1111/bjh.16948.
    PubMed    


  163. YANG Y, Juskevicius R
    T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.
    Br J Haematol. 2020 Jul 7. doi: 10.1111/bjh.16929.
    PubMed    


  164. FOA R, Bonifacio M, Chiaretti S, Curti A, et al
    Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study.
    Br J Haematol. 2020;190:e3-e5.
    PubMed    


  165. DAY JW, Fox TA, Halsey R, Carpenter B, et al
    Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
    Br J Haematol. 2020;190:e80-e83.
    PubMed    


  166. KRUG U, Berdel WE
    Smoking and AML - another piece in the puzzle.
    Br J Haematol. 2020;190:143.
    PubMed    


  167. MALAGOLA M, Bernardi S, Polverelli N, Russo D, et al
    Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?
    Br J Haematol. 2020;190:135-136.
    PubMed    


  168. BARON F, Savani BN
    Graft-versus-host-disease does not help acute lymphoblastic leukaemia patients with measurable residual disease.
    Br J Haematol. 2020;190:22-23.
    PubMed    


  169. ARMAND P, Murawski N, Molin D, Zain J, et al
    Pembrolizumab in relapsed or refractory Richter syndrome.
    Br J Haematol. 2020;190:e117-e120.
    PubMed    


  170. CALVO C, Cabannes-Hamy A, Adjaoud D, Bruno B, et al
    Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:e53-e56.
    PubMed    


  171. KAUR U, Gambhir IS, Khare VR, Singh A, et al
    Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e51-e53.
    PubMed    


  172. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.
    Br J Haematol. 2020;190:236-243.
    PubMed     Abstract available


  173. REA B, Bailey NG
    Acute myeloid leukaemia with t(8;16)(p11.2;p13.3) and erythrophagocytosis.
    Br J Haematol. 2020;190:133.
    PubMed    


  174. JUUL-DAM KL, Ommen HB, Nyvold CG, Walter C, et al
    Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Br J Haematol. 2020;190:198-208.
    PubMed     Abstract available


  175. BENEFORTI L, Dander E, Bresolin S, Bueno C, et al
    Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.
    Br J Haematol. 2020;190:262-273.
    PubMed     Abstract available


  176. ZHOU YL, Wu LX, Peter Gale R, Wang ZL, et al
    Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
    Br J Haematol. 2020;190:274-283.
    PubMed     Abstract available


  177. ZHANG JM, Xu Y, Gale RP, Wu LX, et al
    DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:67-78.
    PubMed     Abstract available


    June 2020
  178. FAVRESSE J, Eucher C, Elsen M, Graux C, et al
    Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.
    Br J Haematol. 2020 Jun 17. doi: 10.1111/bjh.16954.
    PubMed     Abstract available


  179. YANG LH, Zhao Y, Maule J, Rapisardo S, et al
    T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classificat
    Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16886.
    PubMed    


  180. ABRISQUETA P, Delgado J, Alcoceba M, Oliveira AC, et al
    Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16748.
    PubMed     Abstract available


  181. LARSSON K, Mattsson M, Ebrahim F, Glimelius I, et al
    High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16859.
    PubMed    


  182. BATALLER A, Onate G, Diaz-Beya M, Guijarro F, et al
    Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
    Br J Haematol. 2020 Jun 8. doi: 10.1111/bjh.16857.
    PubMed     Abstract available


  183. WILLAN J, King AJ, Djebbari F, Turner GDH, et al
    Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID-19 pandemic.
    Br J Haematol. 2020;189:e224-e227.
    PubMed    


  184. SIENI E, Pegoraro F, Casini T, Tondo A, et al
    Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
    Br J Haematol. 2020;189:e222-e224.
    PubMed    


  185. LANGERAK AW, Davi F, Stamatopoulos K
    Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?
    Br J Haematol. 2020;189:809-810.
    PubMed    


  186. STAHL M, Tallman MS
    Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission.
    Br J Haematol. 2020;189:806-808.
    PubMed    


  187. RAEDLER J, Heyde S, Kolokythas M, Eichinger A, et al
    Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
    Br J Haematol. 2020;189:e251-e254.
    PubMed    


  188. DHAMI SPS, Tirincsi A, Baev D, Krawczyk J, et al
    Theranostic drug test incorporating the bone-marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy.
    Br J Haematol. 2020;189:e254-e258.
    PubMed    


  189. LI XY, Qian JJ, Yang M, Zhang Y, et al
    An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e231-e234.
    PubMed    


  190. DE FIGUEIREDO AF, Land MGP, Ferreira GM, Mencalha A, et al
    Clinical and biological correlates of the expression of select Polycomb complex genes in Brazilian children with acute promyelocytic leukaemia.
    Br J Haematol. 2020;189:e245-e248.
    PubMed    


  191. WU X, Zhang J, Chen Q, Zhou L, et al
    Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
    Br J Haematol. 2020;189:e200-e204.
    PubMed    


  192. GONG Z, Zhou T, Liu H, Tang G, et al
    Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.
    Br J Haematol. 2020;189:e207-e211.
    PubMed    


  193. ZHANG J, Wang Y, Li SQ, Fang L, et al
    Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
    Br J Haematol. 2020;189:1141-1150.
    PubMed     Abstract available


  194. LADIKOU EE, Chevassut T, Pepper CJ, Pepper AG, et al
    Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Br J Haematol. 2020;189:815-825.
    PubMed     Abstract available


  195. RAPONI S, Ilari C, Della Starza I, Cappelli LV, et al
    Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Br J Haematol. 2020;189:853-859.
    PubMed     Abstract available


  196. DIAZ-BEYA M, Labopin M, Maertens J, Alijurf M, et al
    Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
    Br J Haematol. 2020;189:920-925.
    PubMed     Abstract available


  197. AL-ALI HK, Griesshammer M, Foltz L, Palumbo GA, et al
    Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Br J Haematol. 2020;189:888-903.
    PubMed     Abstract available


  198. PATEL BJ, Barot SV, Kuzmanovic T, Kerr C, et al
    Distinctive and common features of moderate aplastic anaemia.
    Br J Haematol. 2020;189:967-975.
    PubMed     Abstract available


    May 2020
  199. THIBAUD S, Tremblay D, Bhalla S, Zimmerman B, et al
    Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16863.
    PubMed     Abstract available


  200. WU Y, Lin H, Xie Q, Chen Q, et al
    COVID-19 in a patient with pre-existing acute lymphoblastic leukemia.
    Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16799.
    PubMed     Abstract available


  201. BALDACINI M, Pop R, Sattler L, Mauvieux L, et al
    Concomitant hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukemia.
    Br J Haematol. 2020 May 5. doi: 10.1111/bjh.16768.
    PubMed     Abstract available


  202. ANTELO G, Mangaonkar AA, Coltro G, Buradkar A, et al
    Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
    Br J Haematol. 2020;189:e104-e108.
    PubMed    


  203. GU X, Saunthararajah Y
    Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.
    Br J Haematol. 2020;189:578-581.
    PubMed    


  204. GRIBBEN JG
    Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?
    Br J Haematol. 2020;189:603-604.
    PubMed    


  205. RAYMOND LM, Funk T, Braziel RM, Fan G, et al
    Mast cell sarcoma with concurrent mast cell leukaemia.
    Br J Haematol. 2020;189:e160-e164.
    PubMed    


  206. ADELAIDE J, Cervera N, Guille A, Murati A, et al
    Gains of EPOR and ERG genes in adult erythroleukaemia.
    Br J Haematol. 2020;189:e174-e177.
    PubMed    


  207. INABA H, Cao X, Chang JY, Karol SE, et al
    Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e177-e181.
    PubMed    


  208. GIUSTI GNN, Jotta PY, Lopes CO, Ganazza MA, et al
    Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e150-e154.
    PubMed    


  209. ROBINSON SE, Harrison CN
    How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Br J Haematol. 2020;189:625-634.
    PubMed     Abstract available


  210. PRIETO-CONDE MI, Jimenez C, Garcia-Alvarez M, Ramos F, et al
    Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
    Br J Haematol. 2020;189:718-730.
    PubMed     Abstract available


  211. ONECHA E, Ruiz-Heredia Y, Martinez-Cuadron D, Barragan E, et al
    Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
    Br J Haematol. 2020;189:672-683.
    PubMed     Abstract available


  212. UDEN T, Bertaina A, Abrahamsson J, Ansari M, et al
    Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
    Br J Haematol. 2020;189:745-750.
    PubMed     Abstract available


  213. MIKLOS U, Strugov V, Lewerin C, Grosicki S, et al
    Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
    Br J Haematol. 2020;189:689-693.
    PubMed     Abstract available


  214. CICIARELLO M, Curti A
    Good news for acute myeloid leukaemia patients from the stroll niche?
    Br J Haematol. 2020;189:597-599.
    PubMed    


  215. CHEN X, Chen H
    BCR-ABL1-positive acute myeloid leukaemia relapsing as acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:591.
    PubMed    


  216. JIANG Y, Li Y, Cheng J, Ma J, et al
    Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
    Br J Haematol. 2020;189:694-706.
    PubMed     Abstract available


  217. ZHAO Y, Maule J, McCracken J, Li Y, et al
    Acute myeloid leukaemia with maturation demonstrates persistent disease with prominent megakaryoblastic differentiation 16 days following induction chemotherapy: an intra-myeloid lineage switch mediated by chemotherapy-induced clonal selection.
    Br J Haematol. 2020;189:e64-e67.
    PubMed    


  218. DULUCQ S, Astrugue C, Etienne G, Mahon FX, et al
    Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
    Br J Haematol. 2020;189:452-468.
    PubMed     Abstract available


  219. JORDAENS S, Cooksey L, Bonney S, Orchard L, et al
    Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:500-512.
    PubMed     Abstract available


  220. DELVECCHIO VS, Sana I, Mantione ME, Vilia MG, et al
    Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
    Br J Haematol. 2020;189:475-488.
    PubMed     Abstract available


  221. MARAJ A, MacEneaney O, Doyle B, Quinn J, et al
    Lysozyme-induced nephropathy: a rare manifestation of chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;189:393.
    PubMed    


  222. LINCH DC, Hills RK, Burnett AK, Gale RE, et al
    The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e81-e86.
    PubMed    


  223. MANOUSOPOULOU A, Wang LD
    ALL the comforts of homing: lymphoblasts find cerebrospinal fluid inhospitable without meningeal cell contact.
    Br J Haematol. 2020;189:395-397.
    PubMed    


  224. VAN DER STRATEN L, Levin MD, Visser O, Posthuma EFM, et al
    Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
    Br J Haematol. 2020;189:574-577.
    PubMed    


  225. BASILE P, Jonart LM, Ebadi M, Johnson K, et al
    The meninges enhance leukaemia survival in cerebral spinal fluid.
    Br J Haematol. 2020;189:513-517.
    PubMed     Abstract available


  226. KLOOS R, van der Sluis IM, Mastrobattista E, Hennink W, et al
    Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
    Br J Haematol. 2020;189:442-451.
    PubMed     Abstract available


    April 2020
  227. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available


  228. FUSTER JL, Molinos-Quintana A, Fuentes C, Fernandez JM, et al
    Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
    Br J Haematol. 2020 Apr 21. doi: 10.1111/bjh.16647.
    PubMed     Abstract available


  229. COGLE CR, Collins B, Turner D, Pettiford LC, et al
    Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
    Br J Haematol. 2020 Apr 1. doi: 10.1111/bjh.16629.
    PubMed    


  230. DHOLARIA B, Savani BN
    Allogeneic haematopoietic cell transplantation after CAR T-cell therapy: safe, effective and contentious.
    Br J Haematol. 2020;189:21-23.
    PubMed    


  231. BERTOLI S, Rieu JB, Recher C, Vergez F, et al
    Large granular lymphocytosis during quizartinib therapy.
    Br J Haematol. 2020;189:7.
    PubMed    


  232. EBADI M, Beckman AK, Yohe SL, Rashidi A, et al
    It's all in the film.
    Br J Haematol. 2020;189:8.
    PubMed    


  233. OSTERROOS A, Eriksson A, Antunovic P, Cammenga J, et al
    Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >/= 60 years.
    Br J Haematol. 2020;189:e13-e16.
    PubMed    


  234. GODWIN CD, Bates OM, Garling EE, Beddoe ME, et al
    The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
    Br J Haematol. 2020;189:e9-e13.
    PubMed    


  235. XU X, Zeng Z, Huo L, Liu H, et al
    High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype.
    Br J Haematol. 2020;189:e23-e27.
    PubMed    


  236. ZHANG Y, Chen H, Song Y, Tan X, et al
    Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Br J Haematol. 2020;189:146-152.
    PubMed     Abstract available


  237. ROESSNER PM, Hanna BS, Ozturk S, Schulz R, et al
    TBET-expressing Th1 CD4(+) T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Emicro-TCL1 mice.
    Br J Haematol. 2020;189:133-145.
    PubMed     Abstract available


  238. WANG Y, Liu QF, Wu DP, Xu LP, et al
    Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients.
    Br J Haematol. 2020;189:153-161.
    PubMed     Abstract available


  239. YANG RY, Yang CX, Lang XP, Duan LJ, et al
    Identification of a novel RUNX1-TACC1 fusion transcript in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e52-e56.
    PubMed    


  240. DO YR, Kwak JY, Kim JA, Kim HJ, et al
    Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
    Br J Haematol. 2020;189:303-312.
    PubMed     Abstract available


  241. ROSSOFF J, Huynh V, Rau RE, Macy ME, et al
    Experience with ponatinib in paediatric patients with leukaemia.
    Br J Haematol. 2020;189:363-368.
    PubMed     Abstract available


  242. AWADA H, Mahfouz RZ, Durrani J, Kishtagari A, et al
    Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation.
    Br J Haematol. 2020;189:318-322.
    PubMed     Abstract available


  243. FRAZZI R, Bizzarri V, Albertazzi L, Cusenza VY, et al
    Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;189:e49-e52.
    PubMed    


  244. BANKAR A, Korula A, Kulkarni UP, Devasia AJ, et al
    Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
    Br J Haematol. 2020;189:269-278.
    PubMed     Abstract available


  245. PIETTE C, Suciu S, Bertrand Y, Uyttebroeck A, et al
    Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.
    Br J Haematol. 2020;189:351-362.
    PubMed     Abstract available


    March 2020
  246. TOUW IP, Sanders MA
    Mutant allelic burden in acute myeloid leukaemia: Why bother?
    Br J Haematol. 2020;188:817-818.
    PubMed    


  247. RICHARDSON AI, Skikne BS, Woodroof J
    Chronic myeloid leukaemia, BCR-ABL1-positive, in accelerated phase with marked eosinophilia with eosinophil atypia.
    Br J Haematol. 2020;188:599.
    PubMed    


  248. RADIA DH, Green A, Oni C, Moonim M, et al
    The clinical and pathological panoply of systemic mastocytosis.
    Br J Haematol. 2020;188:623-640.
    PubMed     Abstract available


  249. XUE YJ, Suo P, Huang XJ, Lu AD, et al
    Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic le
    Br J Haematol. 2020;188:757-767.
    PubMed     Abstract available


  250. PALOMO L, Ibanez M, Abaigar M, Vazquez I, et al
    Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;188:605-622.
    PubMed     Abstract available


  251. KNOFLER R, Lange BS, Paul F, Tiebel O, et al
    Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children.
    Br J Haematol. 2020;188:701-706.
    PubMed     Abstract available


  252. KIM YA, Ju HY, Park HJ, Lee NY, et al
    Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients.
    Br J Haematol. 2020;188:740-744.
    PubMed     Abstract available


  253. CUCCHI DGJ, Bachas C, Klein K, Huttenhuis S, et al
    TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:736-739.
    PubMed     Abstract available


  254. ZHAO C, Jia B, Wang M, Schell TD, et al
    Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.
    Br J Haematol. 2020;188:674-684.
    PubMed     Abstract available


  255. CHIN-YEE B, Sadikovic B, Chin-Yee IH
    Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:652-660.
    PubMed     Abstract available


  256. GIONA F, Malaspina F, Putti MC, Ladogana S, et al
    Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
    Br J Haematol. 2020;188:e101-e105.
    PubMed    


  257. GAUR V, Chaudhary S, Tyagi A, Agarwal S, et al
    Dysregulation of miRNA expression and their prognostic significance in paediatric cytogenetically normal acute myeloid leukaemia.
    Br J Haematol. 2020;188:e90-e94.
    PubMed    


  258. VAN DER STRATEN L, Levin MD, Visser O, Blijlevens NMA, et al
    The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    Br J Haematol. 2020;188:e109-e112.
    PubMed    


  259. GRIBBEN JG
    Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:844-851.
    PubMed     Abstract available


  260. ZHOU C, Zhuang Y, Lin X, Michelson AD, et al
    Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis.
    Br J Haematol. 2020;188:945-961.
    PubMed     Abstract available


  261. HOLTZMAN NG, El Chaer F, Baer MR, Ali O, et al
    Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.
    Br J Haematol. 2020;188:881-887.
    PubMed     Abstract available


  262. ELSTON L, Fegan C, Hills R, Hashimdeen SS, et al
    Increased frequency of CD4(+) PD-1(+) HLA-DR(+) T cells is associated with disease progression in CLL.
    Br J Haematol. 2020;188:872-880.
    PubMed     Abstract available


  263. EYRE TA, Roeker LE, Fox CP, Gohill SH, et al
    The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:918-923.
    PubMed     Abstract available


  264. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
    Br J Haematol. 2020;188:852-859.
    PubMed     Abstract available


    February 2020
  265. DALAL NH, Dores GM, Curtis RE, Linet MS, et al
    Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, 2000-2016.
    Br J Haematol. 2020 Feb 23. doi: 10.1111/bjh.16492.
    PubMed     Abstract available


  266. MONDELAERS V, Ferster A, Uyttebroeck A, Brichard B, et al
    Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Br J Haematol. 2020 Feb 14. doi: 10.1111/bjh.16495.
    PubMed     Abstract available


  267. MATSUO T, Ooi J, Tashiro H, Saito S, et al
    A major break of cord blood bag.
    Br J Haematol. 2020;188:e42-e43.
    PubMed    


  268. HOCKINGS C, Gohil S, Dowse R, Hoade Y, et al
    In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
    Br J Haematol. 2020;188:e53-e57.
    PubMed    


  269. NILSSON MS, Hallner A, Brune M, Nilsson S, et al
    Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
    Br J Haematol. 2020;188:e49-e53.
    PubMed    


  270. GURNEY M, Krawczyk J, Paz Nunez YE
    Megakaryocyte emperipolesis in B-lymphoblastic leukaemia.
    Br J Haematol. 2020;188:348.
    PubMed    


  271. CAPITANO M, Capo-Chichi JM, Minden MD, Chang H, et al
    Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile.
    Br J Haematol. 2020;188:e60-e63.
    PubMed    


  272. BROWN P, Zugmaier G, Gore L, Tuglus CA, et al
    Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.
    Br J Haematol. 2020;188:e36-e39.
    PubMed    


  273. DA COSTA VEF, de Oliveira RD, Traina F, Chahud F, et al
    Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia.
    Br J Haematol. 2020;188:e21-e23.
    PubMed    


  274. SHAHSWAR R, Beutel G, Klement P, Rehberg A, et al
    FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
    Br J Haematol. 2020;188:e11-e15.
    PubMed    


  275. BARON F, Labopin M, Savani BN, Beohou E, et al
    Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.
    Br J Haematol. 2020;188:428-437.
    PubMed     Abstract available


  276. HARA Y, Shiba N, Yamato G, Ohki K, et al
    Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.
    Br J Haematol. 2020;188:528-539.
    PubMed     Abstract available


  277. HANSEN MC, Haferlach T, Nyvold CG
    A decade with whole exome sequencing in haematology.
    Br J Haematol. 2020;188:367-382.
    PubMed     Abstract available


    January 2020

  278. The Management of Acute Leukaemia in Adults.
    Br J Haematol. 2020;188:10-28.
    PubMed    


  279. DEROLF A, Juliusson G, Benson L, Floisand Y, et al
    Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor.
    Br J Haematol. 2020;188:187-191.
    PubMed    


  280. OLIAI C, Schiller G
    How to address second and therapy-related acute myelogenous leukaemia.
    Br J Haematol. 2020;188:116-128.
    PubMed     Abstract available


  281. CHARROT S, Armes H, Rio-Machin A, Fitzgibbon J, et al
    AML through the prism of molecular genetics.
    Br J Haematol. 2020;188:49-62.
    PubMed     Abstract available


  282. HILLS RK
    Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
    Br J Haematol. 2020;188:29-35.
    PubMed     Abstract available


  283. PAUL S, Rausch CR, Jabbour EJ
    The face of remission induction.
    Br J Haematol. 2020;188:101-115.
    PubMed     Abstract available


  284. BURNETT AK, Hills RK, Russell N
    Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
    Br J Haematol. 2020;188:86-100.
    PubMed    


  285. HOKLAND P
    AML - a signature disease in haematology.
    Br J Haematol. 2020;188:7.
    PubMed    


  286. LOKE J, Malladi R, Moss P, Craddock C, et al
    The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.
    Br J Haematol. 2020;188:129-146.
    PubMed     Abstract available


  287. MO X, Chen H
    Acute promyelocytic leukaemia with myeloperoxidase-negative rectangular inclusions.
    Br J Haematol. 2020;188:8.
    PubMed    


  288. HAFERLACH T, Schmidts I
    The power and potential of integrated diagnostics in acute myeloid leukaemia.
    Br J Haematol. 2020;188:36-48.
    PubMed     Abstract available


  289. GARCIA SPEZZA E, Brethon B, Petit A, Mazingue F, et al
    Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
    Br J Haematol. 2020;188:170-173.
    PubMed    


  290. GHOSH A, Barba P, Perales MA
    Checkpoint inhibitors in AML: are we there yet?
    Br J Haematol. 2020;188:159-167.
    PubMed     Abstract available


  291. JONES L, McCarthy P, Bond J
    Epigenetics of paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:63-76.
    PubMed     Abstract available


  292. GHANNAM J, Dillon LW, Hourigan CS
    Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
    Br J Haematol. 2020;188:77-85.
    PubMed     Abstract available


  293. WANG T, Wang Z, Zhang L, Wen L, et al
    Identification of a novel TFG-FGFR1 fusion gene in an acute myeloid leukaemia patient with t(3;8)(q12;p11).
    Br J Haematol. 2020;188:177-181.
    PubMed    


  294. BARRETT AJ
    Acute myeloid leukaemia and the immune system: implications for immunotherapy.
    Br J Haematol. 2020;188:147-158.
    PubMed     Abstract available


  295. PIANIGIANI G, Betti C, Bigerna B, Rossi R, et al
    PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1.
    Br J Haematol. 2020;188:184-187.
    PubMed    


  296. JIANG G, Atenafu EG, Capo-Chichi JM, Minden MD, et al
    Prognostic relevance of CD123 expression in adult AML with normal karyotype.
    Br J Haematol. 2020;188:181-184.
    PubMed    


  297. ESPARZA S, Muluneh B, Galeotti J, Matson M, et al
    Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia.
    Br J Haematol. 2020;188:173-177.
    PubMed    


  298. YIN J, Zhu S, Luo Y, Lin Z, et al
    Acute myeloid leukaemia with Auer rods within pseudo-Chediak-Higashi granules.
    Br J Haematol. 2020;188:9.
    PubMed    


  299. KATAGIRI S, Gotoh A, Ohyashiki K
    Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia.
    Br J Haematol. 2020;188:332-334.
    PubMed    


  300. RAFEI H, Kantarjian HM, Jabbour EJ
    Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Br J Haematol. 2020;188:207-223.
    PubMed     Abstract available


    November 2019
  301. ROSADAS C, Puccioni-Sohler M, Oliveira ACP, Casseb J, et al
    Adult T-cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed?
    Br J Haematol. 2019 Nov 19. doi: 10.1111/bjh.16318.
    PubMed    


    October 2019
  302. NYLAND SB, Feith DJ, Poss M, Olson TL, et al
    Retroviral sero-reactivity in LGL leukaemia patients and family members.
    Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16223.
    PubMed     Abstract available


    July 2019
  303. FERRETTI A, Baldacci E, Miulli E, Canichella M, et al
    Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16114.
    PubMed    


  304. DOMINGUEZ-PINILLA N, Martinez-Zamorano E, Campos-Martin Y, Algara Plana P, et al
    Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia.
    Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089.
    PubMed    


    June 2019
  305. SAKAMOTO K, Shiba N, Deguchi T, Kiyokawa N, et al
    Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16080.
    PubMed     Abstract available


    May 2019
  306. KHOGEER H, Rahman H, Jain N, Angelova EA, et al
    Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15960.
    PubMed     Abstract available


  307. TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
    Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
    Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
    PubMed     Abstract available


    February 2019
  308. KHASHAB T, Hagemeister F, Romaguera JE, Fanale MA, et al
    Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 28. doi: 10.1111/bjh.15814.
    PubMed     Abstract available


  309. BURKHARDT B, Hermiston ML
    Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
    Br J Haematol. 2019 Feb 27. doi: 10.1111/bjh.15793.
    PubMed     Abstract available


  310. MIYAMURA T, Moritake H, Nakayama H, Tanaka S, et al
    Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15799.
    PubMed     Abstract available


  311. O'REILLY MA, Govender D, Kirkwood AA, Vora A, et al
    The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15798.
    PubMed    


    January 2019
  312. BATALLER A, Combalia A, Garcia-Herrera A, Estrach T, et al
    Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15744.
    PubMed    


    August 2018
  313. SU C, Bai HX, Xiao R
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some of the apparent ethnic dispa
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15526.
    PubMed    


  314. LO BELLO G, Naresh KN
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities.
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15527.
    PubMed    


    July 2018
  315. AILAWADHI S, Dholaria BR, Khurana S, Sher T, et al
    Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: